Cardiac Hypertrophy and Fibrosis in the Metabolic Syndrome: A Role for Aldosterone and the Mineralocorticoid Receptor
Author(s) -
Eric E. Essick,
Flora Sam
Publication year - 2011
Publication title -
international journal of hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.744
H-Index - 37
eISSN - 2090-0392
pISSN - 2090-0384
DOI - 10.4061/2011/346985
Subject(s) - medicine , aldosterone , metabolic syndrome , mineralocorticoid receptor , endocrinology , fibrosis , adiponectin , cardiac fibrosis , mineralocorticoid , obesity , adipose tissue , muscle hypertrophy , heart failure , left ventricular hypertrophy , renin–angiotensin system , adipokine , angiotensin ii , pathogenesis , cardiology , receptor , blood pressure , leptin , insulin resistance
Obesity and hypertension, major risk factors for the metabolic syndrome, render individuals susceptible to an increased risk of cardiovascular complications, such as adverse cardiac remodeling and heart failure. There has been much investigation into the role that an increase in the renin-angiotensin-aldosterone system (RAAS) plays in the pathogenesis of metabolic syndrome and in particular, how aldosterone mediates left ventricular hypertrophy and increased cardiac fibrosis via its interaction with the mineralocorticoid receptor (MR). Here, we review the pertinent findings that link obesity with elevated aldosterone and the development of cardiac hypertrophy and fibrosis associated with the metabolic syndrome. These studies illustrate a complex cross-talk between adipose tissue, the heart, and the adrenal cortex. Furthermore, we discuss findings from our laboratory that suggest that cardiac hypertrophy and fibrosis in the metabolic syndrome may involve cross-talk between aldosterone and adipokines (such as adiponectin)
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom